Phase 1 Clinical Trials in Psychopharmacology

Eef Theunissen*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterAcademic

Abstract

Phase 1 trials are an important step in drug development and are usually the first that involve human participants. Their main objective is most often to determine a safe and effective dose range for further clinical development of the drug. Specific guidelines and regulations apply to this type of trial and have been laid down by health authorities. These guidelines aim to minimize the risks and maximize the benefits and concern the trial’s objective, design, methodology, and organization. To obtain approval for a clinical trial, a Clinical Trial Application, outlining how these guidelines are implemented, has to be reviewed and approved by an ethical committee. In this chapter, an overview is given of the unique features of phase 1 trials, and the specific guidelines that apply to setting up, submitting, and conducting phase 1 trials in the European Union.
Original languageEnglish
Title of host publicationModern CNS Drug Discovery
Subtitle of host publicationNovel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval
PublisherSpringer
Pages385-393
Number of pages9
Edition2
ISBN (Electronic)9783031619922
ISBN (Print)9783031619915
DOIs
Publication statusPublished - 2024

Fingerprint

Dive into the research topics of 'Phase 1 Clinical Trials in Psychopharmacology'. Together they form a unique fingerprint.

Cite this